𝔖 Bobbio Scriptorium

✦ LIBER ✦

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER) trial: study design and rationale

✍ Scribed by The TRA•CER Executive; Steering Committees

Book ID: 116191842
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 304 KB
Volume: 158
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2009.07.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evaluation of a novel antiplatelet agent

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial

✍ David A. Morrow; Benjamin M. Scirica; Keith A.A. Fox; Gail Berman; John Strony; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 329 KB

Study design and rationale for the Stabi

Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome

✍ Michelle L. O'Donoghue; Eugene Braunwald; Harvey D. White; Patrick Serruys; Ph. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 300 KB

Comparison of ticagrelor, the first reve

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

✍ Stefan James; Axel Åkerblom; Christopher P. Cannon; Håkan Emanuelsson; Steen Hus 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Comparison of ticagrelor, the first reve

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

✍ Stefan James; Axel Åkerblom; Christopher P. Cannon; Håkan Emanuelsson; Steen Hus 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 139 KB

The Early Glycoprotein IIb/IIIa Inhibiti

The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale

✍ Robert P. Giugliano; L. Kristin Newby; Robert A. Harrington; C. Michael Gibson; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Rationale and design of the Anti-Xa Ther

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

✍ C. Michael Gibson; Jessica L. Mega; Paul Burton; Shinya Goto; Freek Verheugt; Ch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 428 KB